Reporting owner · CIK 0001701247
Collins Helen Louise
Visual SEC Form 4 history across 1 companies, 10 transactions and 3 filings.
CMOCHIEF MEDICAL OFFICEREnliven Therapeutics, Inc.
Open-market mix
0%buys
Open-market buy performance
90-day forward return on this insider's open-market purchases
Forward return is not available yet
We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for this insider's their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.
Monthly open-market activity
Reported purchase and sale transaction counts
Buys Sells
Net value flow
Buys minus sells
Feb 25
$0
Aug 26
−$292.9K
Sep 26
−$251.8K
Transaction texture
Ownership and ticket size
Average P/S size$108.9K
Median P/S size$93.5K
Direct10
Indirect0
Sep 17, 2026exercise
Filing-only signals
Deterministic matches in this insider's history
Latest Form 4 facts
Quick context from source filings
Latest transaction
sale at Enliven Therapeutics, Inc. on Sep 17, 2026 valued at $12,356.
Review SEC filingLatest buy
No open-market insider purchase is available.
Associated companies
Visual map of known reporting history
Latest insider transactions
Form 4 filings from available history. Click any column to sort; click it again to flip the order.
| ID | Ticker | Insider | Role | Type | Shares | Value | Code | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|
| #226931 | ELVN | Collins Helen Louise | CMO | exercise10b5-1 | 5.00k | $0 | M | 09/21 | 09/17 |
| #226930 | ELVN | Collins Helen Louise | CMO | sale10b5-1 | 240 | -$1.23M | S | 09/21 | 09/17 |
| #226929 | ELVN | Collins Helen Louise | CMO | sale10b5-1 | 1.84k | -$9.35M | S | 09/21 | 09/17 |
| #226928 | ELVN | Collins Helen Louise | CMO | sale10b5-1 | 2.91k | -$14.5M | S | 09/21 | 09/17 |
| #226927 | ELVN | Collins Helen Louise | CMO | exercise10b5-1 | 5.00k | $1.24M | M | 09/21 | 09/17 |
| #11063 | ELVN | Collins Helen Louise | CMO | exercise10b5-1 | 5.00k | $0 | M | 08/19 | 08/17 |
| #11062 | ELVN | Collins Helen Louise | CMO | sale10b5-1 | 1.10k | -$6.52M | S | 08/19 | 08/17 |
| #11061 | ELVN | Collins Helen Louise | CMO | sale10b5-1 | 3.90k | -$22.7M | S | 08/19 | 08/17 |
| #11060 | ELVN | Collins Helen Louise | CMO | exercise10b5-1 | 5.00k | $1.24M | M | 08/19 | 08/17 |
| #79831 | ELVN | Collins Helen Louise | CMO | grant | 171k | $0 | A | 02/10/2025 | 02/06/2025 |
Collins Helen Louise Insider Activity FAQ
SEC Form 4 context
Who is Collins Helen Louise?
Collins Helen Louise is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001701247.
Which companies has Collins Helen Louise reported transactions for?
Enliven Therapeutics, Inc.
When was Collins Helen Louise's latest insider buy?
No open-market insider purchase is available for this period.
When was Collins Helen Louise's latest insider sale?
sale at Enliven Therapeutics, Inc. on Sep 17, 2026 valued at $12,356.
Where can I see the original SEC filings?
Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.
Are performance metrics included?
This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.